Bevacizumab with FOLFIRI or XELIRI in the first-line therapy of metastatic colorectal carcinoma: the results from Czech observational registry

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00209805%3A_____%2F15%3A%230000693" target="_blank" >RIV/00209805:_____/15:#0000693 - isvavai.cz</a>

Result on the web

<a href="http://ar.iiarjournals.org/content/35/6/3455.abstract" target="_blank" >http://ar.iiarjournals.org/content/35/6/3455.abstract</a>

DOI - Digital Object Identifier

—

Result language

angličtina

Original language name

Bevacizumab with FOLFIRI or XELIRI in the first-line therapy of metastatic colorectal carcinoma: the results from Czech observational registry

Original language description

Aim: To retrospectively compare the efficacy of two irinotecan-based chemotherapy regimens combined with bevacizumab in first-line therapy of metastatic colorectal cancer (mCRC). Patients and Methods: The data of 558 patients with mCRC treated with first-line bevacizumab plus irinotecan-containing regimen were obtained from the national CORECT registry that collects data of all patients with mCRC treated with targeted-agents. The treatment outcomes of patients treated with bevacizumab plus irinotecan, 5-fluorouracil and folinic acid (FOLFIRI) were compared to patients treated with bevacizumab plus irinotecan and capecitabine (XELIRI). Results: Among 4,312 patients with CRC treated with bevacizumab, only 13% (558) received irinotecan-based chemotherapy. No significant differences were observed in terms of progression-free survival and overall survival between FOLFIRI and XELIRI groups. Moreover, the toxicity of both regimens was also comparable. Conclusion: This retrospective analysis confirms the comparable activity of FOLFIRI and XELIRI regimens when combined with bevacizumab.

Czech name

—

Czech description

—

Type

J_x - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)

CEP classification

FD - Oncology and haematology

OECD FORD branch

—

Project

—

Continuities

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Publication year

2015

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Name of the periodical

Anticancer research

ISSN

0250-7005

e-ISSN

—

Volume of the periodical

35

Issue of the periodical within the volume

6

Country of publishing house

GR - GREECE

Number of pages

7

Pages from-to

3455-3461

UT code for WoS article

000355273800039

EID of the result in the Scopus database

2-s2.0-84931346472